MedPath

Safety and immunogenicity of a live attenuated SA14-14-2 JE Vaccine (CD.JEVAX®) as a booster dose after priming with chimeric JE Vaccine (IMOJEV®) in Thai childre

Not Applicable
Recruiting
Conditions
Safety and immunogenicity of a live attenuated SA14&#45
14&#45
2 JE Vaccine
Japanese Encephalitis
Live Attenuated
Vaccine
Registration Number
TCTR20151213001
Lead Sponsor
Chengdu Institute of Biological Products, Chengdu, PR China
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

A. aged 1-5 years.
B. Have been vaccinated against encephalitis JE kind IMOJEV just a single dose at least 12 months and have never been vaccinated against encephalitis JE other.
C. Be healthy according to history And physical examination by a physician
D. Can pursue a research project in about 28-35 days.
E. Signed a consent form to participate as a volunteer voluntarily. The parent or legal guardian legitimacy of volunteers.
F. Not received any vaccine within 30 days prior to enrollment.

Exclusion Criteria

A. Volunteers have been vaccinated against encephalitis JE other.
Except IMOJEV®
B. Volunteers receive any vaccine within 30 days prior to enrollment.
C. Volunteer allergy to any vaccine component.
D. Volunteers are malaise thermometer ≥38º C in the armpit on the project.
E. Volunteers receive blood or blood products within 3 months prior to enrollment or expects to receive blood or blood products within one month after receiving the vaccine.
F. Volunteers or suspected immune deficiency. Including severe liver disease, kidney failure, cancer, autoimmune diseases would not grow themselves, the use of immunosuppressants, the use of steroids edible.
(Except the steroid spray of respiratory tract)
G. Any clinical situation in which doctors are of the opinion that the project may be a barrier to education, and interpretation of research results

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath